Harmony Biosciences Holdings Inc. (HRMY) News

Harmony Biosciences Holdings Inc. (HRMY): $32.04

0.62 (-1.90%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

A

Add HRMY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#26 of 340

in industry

Filter HRMY News Items

HRMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HRMY News Highlights

  • HRMY's 30 day story count now stands at 6.
  • Over the past 12 days, the trend for HRMY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about HRMY are GMAB and RARE.

Latest HRMY News From Around the Web

Below are the latest news stories about HARMONY BIOSCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate HRMY as an investment opportunity.

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks.

Josh Enomoto on InvestorPlace | December 17, 2023

Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On

While all eyes may be on the usual suspects of market hype and influence, astute investors with a contrarian streak may want to consider Russell 2000 stocks.

Josh Enomoto on InvestorPlace | December 8, 2023

HRMY or GMAB: Which Is the Better Value Stock Right Now?

HRMY vs. GMAB: Which Stock Is the Better Value Option?

Yahoo | December 7, 2023

HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1

Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal detection study evaluating the safety and efficacy of pitolisant in adult patients with myotonic dystrophy type 1 (DM1).

Yahoo | December 7, 2023

16 Most Undervalued Small-Cap Stocks To Buy According To Hedge Funds

In this article, we will take a look at the 16 most undervalued small-cap stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Small-Cap Stocks To Buy According To Hedge Funds. Despite strong signs that the central bank would be ready to hit brakes on its […]

Yahoo | December 5, 2023

HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING

Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, will present caregiver-reported impacts of 22q11.2 deletion syndrome (22q) and data from the Phase 2 INSPIRE trial at the American College of Neuropsychopharmacology Annual Meeting from December 3-6, 2023.

Yahoo | December 5, 2023

Wall Street Analysts Predict a 44.38% Upside in Harmony Biosciences Holdings, Inc. (HRMY): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 29, 2023

HRMY vs. REGN: Which Stock Is the Better Value Option?

HRMY vs. REGN: Which Stock Is the Better Value Option?

Yahoo | November 21, 2023

Is Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Most readers would already be aware that Harmony Biosciences Holdings' (NASDAQ:HRMY) stock increased significantly by...

Yahoo | November 19, 2023

HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCE

Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY on Thursday, November 30, 2023, at 9:00 a.m. ET.

Yahoo | November 16, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!